Amphivena Therapeutics, Inc. is a privately held, clinical-stage, immuno-oncology company that is developing a novel platform of dual-action biologics that relieve immune suppression and drive T-cell activation and polarization to restore anti-cancer immunity in patients
The fundamental challenge in immuno-oncology is that a majority of patients do not respond to immunotherapies. Cancer patients exhibit tumor-induced immune suppression mediated by immune cell types such as myeloid derived suppressor cells (MDSC). T cell activating therapies can also trigger autoregulatory immune modulation, via MDSC recruitment.
Our proprietary platform is designed to potently and selectively deplete MDSC and to drive the activation and repolarization of T cells to relieve immune suppression and restore anti-cancer immunity in patients.
The AMPHIVENA ReSTORE™ platform provides dual-action biologics that relieve immune suppression and activate
T cell effector function in cancer patients
The platform can be engineered with additional solid tumor targeting modalities to add functionality such as directed tumor cell killing
Our lead candidate, AMV564, is currently in clinical studies in both solid tumor and hematologic cancers
We are advancing additional bivalent, multi-target candidates through preclinical development
April 12, 2021
Amphivena Therapeutics today presents translational data for the Company’s lead clinical candidate from a Phase 1 study in patients with advanced solid tumors. The poster, entitled “MDSC Suppress the T Cell Repertoire and Contribute to a Pathologic Cytokine Milieu in Cancer Patients,” (Abstract 528) is presented today at the American Association for Cancer Research (AACR) 2021 Virtual Annual Meeting…..
December 16, 2020
South San Francisco, CA – Dec 16, 2020 — Amphivena Therapeutics, a clinical-stage oncology company focused on developing a platform of bivalent T-cell engagers that restore anti-cancer immunity in patients, today announced the first patient has been dosed in the Phase 1 dose expansion study evaluating AMV564, an investigational, first-in-class agent that depletes myeloid derived suppressor cells (MDSC) and activates T cells, in adult patients with selected solid tumor indications….
December 6, 2020
South San Francisco, CA – Dec 6, 2020 — Amphivena Therapeutics, a clinical-stage oncology company focused on developing immunotherapeutics that restore anti-cancer immunity in patients, today presented data on a novel assay for selection of acute myeloid leukemia (AML) patients for treatment with AMV564, at the 62nd Annual American Society of Hematology Meeting and Exposition (ASH 2020), taking place virtually from December 5-8, 2020….
November 9, 20202020 Society for Immunotherapy of Cancer (SITC) Annual Meeting Poster Presentation (Clinical Update)